Penn analysis shows low risk of secondary cancers following CAR T cell therapy

The development of any type of second cancer following CAR T cell therapy is a rare occurrence, as found in an analysis of more than 400 patients treated at Penn Medicine, researchers from the Perelman School of Medicine at the University of Pennsylvania reported today in Nature Medicine.

SABR Offers New Hope for Older Patients With Inoperable Kidney Cancer

SAN DIEGO — Stereotactic ablative body radiotherapy (SABR) was an effective, noninvasive strategy for treating primary renal cell carcinoma (RCC) in patients who were not

October 2, 2023

Chemotherapy plus immunotherapy improves survival in patients with metastatic urothelial cancer

A clinical trial co-led by Mount Sinai researchers is the first to show that using chemotherapy with immunotherapy resulted in improved survival in patients with

October 23, 2023

Does losing your sense of purpose signal the onset of cognitive decline?

A recent study in JAMA Network Open explores how an individual’s sense of purpose in life changes before and after the onset of cognitive impairment,

September 19, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.